Marc Ditmarsch

918 total citations · 2 hit papers
41 papers, 554 citations indexed

About

Marc Ditmarsch is a scholar working on Surgery, Economics and Econometrics and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Marc Ditmarsch has authored 41 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Surgery, 16 papers in Economics and Econometrics and 14 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Marc Ditmarsch's work include Lipoproteins and Cardiovascular Health (31 papers), Pharmaceutical Economics and Policy (13 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (11 papers). Marc Ditmarsch is often cited by papers focused on Lipoproteins and Cardiovascular Health (31 papers), Pharmaceutical Economics and Policy (13 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (11 papers). Marc Ditmarsch collaborates with scholars based in United States, Netherlands and Australia. Marc Ditmarsch's co-authors include John J.P. Kastelein, Michael H. Davidson, Stephen J. Nicholls, Douglas Kling, Danielle Curcio, Nick S. Nurmohamed, Andrew Hsieh, Mary R. Dicklin, Nicholas John and Adam J. Nelson and has published in prestigious journals such as The Lancet, Circulation and Nature Medicine.

In The Last Decade

Marc Ditmarsch

37 papers receiving 529 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial

2022 113 citations Stephen J. Nicholls, Marc Ditmarsch et al. Nature Medicine profile →
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial

2025 17 citations Ashish Sarraju, Danielle M. Brennan et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marc Ditmarsch United States	11	451	245	122	119	90	41	554
John T. Monyak United States	11	449 1.0×	246 1.0×	75 0.6×	59 0.5×	123 1.4×	23	652
H Vaverková Czechia	13	226 0.5×	200 0.8×	170 1.4×	76 0.6×	46 0.5×	71	526
C. Abletshauser Germany	16	386 0.9×	179 0.7×	264 2.2×	105 0.9×	50 0.6×	36	711
Paula Robinson United States	4	526 1.2×	223 0.9×	141 1.2×	168 1.4×	128 1.4×	6	679
P.J. Barter Australia	9	539 1.2×	300 1.2×	167 1.4×	121 1.0×	43 0.5×	13	742
Valasia V. Athyrou Greece	6	565 1.3×	314 1.3×	173 1.4×	99 0.8×	209 2.3×	6	689
Kate Tsirtsonis United States	5	512 1.1×	128 0.5×	73 0.6×	78 0.7×	227 2.5×	6	618
Hans J. Avis Netherlands	12	496 1.1×	239 1.0×	136 1.1×	123 1.0×	90 1.0×	18	630
J. Kastelein Netherlands	8	541 1.2×	312 1.3×	161 1.3×	156 1.3×	96 1.1×	28	785
Koji Yanagi Japan	10	316 0.7×	177 0.7×	107 0.9×	99 0.8×	23 0.3×	19	422

Countries citing papers authored by Marc Ditmarsch

Since Specialization

Citations

This map shows the geographic impact of Marc Ditmarsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Ditmarsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Ditmarsch more than expected).

Fields of papers citing papers by Marc Ditmarsch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Ditmarsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Ditmarsch. The network helps show where Marc Ditmarsch may publish in the future.

Co-authorship network of co-authors of Marc Ditmarsch

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Ditmarsch. A scholar is included among the top collaborators of Marc Ditmarsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Ditmarsch. Marc Ditmarsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ray, Kausik K., Michael Szarek, Ann Marie Návar, et al.. (2025). Effect of Obicetrapib on New Onset Diabetes In Patients with Elevated LDL-C Receiving Maximally Tolerated Statin Therapy: Pooled Analyses of the Broadway and Brooklyn Trials. Journal of clinical lipidology. 19(3). e116–e117. 1 indexed citations

Niesor, Eric J., et al.. (2025). Low-dose obicetrapib significantly increases concentrations of lipophilic antioxidants, APOE, and S1P in HDL subfractions. Atherosclerosis. 407. 119512–119512. 1 indexed citations

Ditmarsch, Marc, et al.. (2025). Efficacy of obicetrapib across the spectrum of background lipid-lowering therapies: pooled analyses of the BROADWAY and BROOKLYN randomized trials. European Journal of Preventive Cardiology.

Nicholls, Stephen J., Kausik K Ray, Michael Szarek, et al.. (2025). Impact of the cholesteryl ester transfer protein inhibitor, Obicetrapib, on lipoprotein(a) levels: Pooled data from phase 3 clinical trials. Journal of clinical lipidology. 19(3). e99–e100. 1 indexed citations

Nicholls, Stephen C., Adam Nelson, Marc Ditmarsch, et al.. (2025). † Safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia. Journal of clinical lipidology. 19(3). e91–e91. 1 indexed citations

Sarraju, Ashish, Danielle M. Brennan, Alix Hayden, et al.. (2025). Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. 405(10491). 1757–1768. 17 indexed citations breakdown →

Szarek, Michael, Philip Scheltens, Everard G.B. Vijverberg, et al.. (2025). Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease. The Journal of Prevention of Alzheimer s Disease. 13(1). 100394–100394. 1 indexed citations

Hsieh, Andrew, et al.. (2024). †Obicetrapib Demonstrates Significant Reductions Of Lp(a) On Top Of High-intensity Statins. Journal of clinical lipidology. 18(4). e563–e564. 1 indexed citations

Kastelein, J., Marc Ditmarsch, Andrew Hsieh, Mary R. Dicklin, & Michael Davidson. (2024). Obicetrapib does not accumulate in adipose tissue: Results from studies in man and non-human primates. Atherosclerosis. 395. 118209–118209. 1 indexed citations

10.

Schmidt, Amand F., Michael H. Davidson, Marc Ditmarsch, John J.P. Kastelein, & Chris Finan. (2024). Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis. Alzheimer s Research & Therapy. 16(1). 228–228. 2 indexed citations

11.

Zhang, Jing, Guoying Cao, Yong Huo, et al.. (2024). A Randomized, Parallel, Open‐Label, Single‐Dose and Multiple‐Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China. The Journal of Clinical Pharmacology. 65(1). 96–107. 3 indexed citations

12.

Kastelein, John J.P., Andrew Hsieh, Mary R. Dicklin, Marc Ditmarsch, & Michael H. Davidson. (2023). Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Current Atherosclerosis Reports. 26(2). 35–44. 31 indexed citations

13.

Ballantyne, Christie M., Marc Ditmarsch, John J.P. Kastelein, et al.. (2023). Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. Journal of clinical lipidology. 17(4). 491–503. 53 indexed citations

14.

Mehta, Nehal N., Katerina Dangas, Marc Ditmarsch, et al.. (2023). The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease. Pharmacological Research. 197. 106972–106972. 8 indexed citations

15.

Nicholls, Stephen J., Marc Ditmarsch, John J.P. Kastelein, et al.. (2022). Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nature Medicine. 28(8). 1672–1678. 113 indexed citations breakdown →

16.

Held, Peter, Anders Himmelmänn, & Marc Ditmarsch. (2016). Ticagrelor for the Treatment of Atherosclerotic Disease: Insights From the Parthenon Clinical Development Program. Future Cardiology. 12(4). 405–418. 8 indexed citations

17.

Erdmann, Erland, Robert M. Califf, Hertzel C. Gerstein, et al.. (2015). Effects of the dual peroxisome proliferator–activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. American Heart Journal. 170(1). 117–122. 25 indexed citations

18.

Hermans, Michel, et al.. (2007). Centralised PAN-European survey on the under-treatment of hypercholesterolemia in patients using lipid lowering drugs (CEPHEUS). Value in Health. 10(6). 1 indexed citations

19.

Vidt, Donald G., Susan S. Harris, Fergus McTaggart, et al.. (2006). Effect of Short-Term Rosuvastatin Treatment on Estimated Glomerular Filtration Rate. The American Journal of Cardiology. 97(11). 1602–1606. 61 indexed citations

20.

Ditmarsch, Marc. (2003). Endoluminal aortic shunting for distal perfusion during thoracic aortal cross-clamping in a pig model. Cardiovascular Surgery. 11(4). 287–293. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact